GPT and hepatocellular carcinoma: A consistent pattern for lower 5‐, 10‐ and 15‐year HCC incidence for treated versus untreated patients in subgroup analyses was observed, including patients ≥45 years of age (p = .04), male sex (p = .03), ALT below the ULN (35 U/L for males and 25 U/L for females) (p = .04), HBV‐DNA >1000 IU/mL (p = .007) and HBeAg+ (p = .0005).